News

Data from the phase 2 ReNeu study presented at the 2024 ASCO Annual Meeting support this priority review designation.

In an interview, Anil Parwani, MD, PhD, discussed how artificial intelligence can be used in medical education and training, as well as its role in personalized medicine.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

New data on zongertinib for HER2-positive non–small cell lung cancer will be presented at the IASLC 2024 World Conference on Lung Cancer, shedding light on its potential as a novel treatment option for this patient population.

The TruSight Oncology Comprehensive test has been approved by the FDA as a companion diagnostic for NTRK-fusion positive solid tumors and RET-fusion positive non–small cell lung cancer.

The innovative bispecific antibody INV724 targets GD2 and B7-H3 with high specificity for neuroblastoma.

The FDA’s Oncologic Drug Advisory Committee will meet on September 26, 2024, to discuss PD-L1 cutoffs for immune checkpoint inhibitors in gastric, gastroesophageal, and esophageal cancers.

Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses the artificial intelligence (AI) technology that is currently being used at his institution.

The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma.

Habte Yimer, MD, discussed the findings from the phase 3 ALPINE trial and explored how these results are shaping clinical decisions in chronic lymphocytic leukemia treatment.

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

CAR T-cell therapy is a game-changing treatment, but it is not without the potential for serious adverse effects. Researchers and physicians still wonder about the incidence and prevalence of these risks.

Aakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.

T-DXd receives FDA breakthrough therapy designation for HR+/HER2-low breast cancer and real-world data confirms brexu-cel’s efficacy in relapsed/refractory B-cell ALL. A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.

LITESPARK-005 showed that belzutifan improved progression-free survival and objective response vs everolimus in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint and antiangiogenic therapies.

When given in combination, sonrotoclax and zanubrutinib shows promise in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, according to data from the BGB-11417-101 study.

With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.

An independent data monitoring committee assessed that the PRECISION1 trial of nab-sirolimus in solid tumors would not meet an efficacy threshold to support the agent’s accelerated approval.

64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.

The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post multiple therapies.

The VISTA-101 clinical trial is investigating KVA12123, a VISTA-blocking immunotherapy, in advanced solid tumors.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.

Backed by the phase 1 ARTEMIS-001 trial, the FDA has granted GSK5764227 a breakthrough therapy designation for the treatment of extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Hope S. Rugo, MD, FASCO, discussed data from the ELEVATE trial of elacestrant combinations in ER-positive/HER2-negative metastatic breast cancer.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.